Can I read CRISPR/Cas mediated epigenome editing for cancer therapy on EtoBox?

CRISPR/Cas mediated epigenome editing for cancer therapy by Imran Ansari; Animesh Chaturvedi; Deepak Chitkara; Saurabh Singh is a Biochemistry, Genetics and Molecular Biology article available to read on EtoBox.

What is CRISPR/Cas mediated epigenome editing for cancer therapy about?

The understanding of the relationship between epigenetic alterations, their effects on gene expression and the knowledge that these epigenetic alterations are reversible, have opened up new therapeutic pathways for treating various diseases, including cancer. This has led the research for a better understanding of the mechanism and pathways of carcinogenesis and provided the opportunity to develop the therapeutic approaches by targeting such pathways. Epi-drugs, DNA methyl transferase (DNMT) inhibitors and histone deacetylase (HDAC) inhibitors are the best examples of epigenetic therapies with clinical applicability. Moreover, precise genome editing technologies such as CRISPR/Cas has proven their efficacy in epigenome editing, including the alteration of epigenetic markers, such as DNA methylation or histone modification. The main disadvantage with DNA gene editing technologies is off-target DNA sequence alteration, which is not an issue with epigenetic editing. It is known that cancer is linked with epigenetic alteration, and thus CRISPR/Cas system shows potential for cancer therapy via epigenome editing. This review outlines the epigenetic therapeutic approach for cancer therapy

Who reads CRISPR/Cas mediated epigenome editing for cancer therapy?

Author

Imran Ansari; Animesh Chaturvedi; Deepak Chitkara; Saurabh Singh

Publisher

Elsevier BV

Published

2021

Language

EN

Field

Biochemistry, Genetics and Molecular Biology (Life Sciences)